ENANTA PHARMACEUTICALS INC business relationships
Companies named in ENANTA PHARMACEUTICALS INC’s 10-K filed 2025-11-19, and public companies whose annual reports name ENANTA PHARMACEUTICALS INC. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 70 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in ENANTA PHARMACEUTICALS INC’s annual report 7
“Gilead has been awarded the contract in Louisiana and other states and AbbVie has been awarded the contract in Washington and other states.” SEC filing
“Collaborative Development and License Agreement between the Company and Abbott Laboratories, dated November 27, 2006; as amended by a First Amendment to Collaborative Development and License Agreement dated January 27, 2009 and a Second Amendment to Collaborative Development and License Agreement da...” SEC filing
“Today, these patients are estimated to represent the majority of HCV patients in over 50 countries where MAVYRET/MAVIRET is sold by AbbVie and where MAVYRET/MAVIRET remains the only 8-week pan-genotypic HCV treatment.” SEC filing
“Gilead has been awarded the contract in Louisiana and other states and AbbVie has been awarded the contract in Washington and other states.” SEC filing
“Under this collaboration, we have received royalty payments from AbbVie totaling $954 million through September 30, 2025.” SEC filing
“Collaboration and License Agreement with AbbVie” SEC filing
“the amount of our retained portion of royalties generated from MAVYRET/MAVIRET sales under our existing collaboration with AbbVie;” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.